How Semaglutide Is Made: Recombinant Yeast vs. Synthetic Peptide
Novo Nordisk makes the semaglutide in Ozempic and Wegovy by growing a precursor peptide in genetically engineered yeast and then chemically attaching a fatty-acid side chain. The alternative is to build the peptide chemically, one amino acid at a time. Both routes can produce the same molecule, but they leave behind different impurities, and that difference is what FDA's rules for generic peptides and its warnings about compounding ingredients are built around.
Key takeaways
- Europe's regulator describes Novo's semaglutide as made "using recombinant DNA technology in yeast (Saccharomyces cerevisiae) and chemical modification."
- Synthetic routes avoid yeast-derived impurities but can introduce peptide-related impurities, such as sequences with an extra or missing amino acid.
- FDA's framework for synthetic generic peptides proposed that each peptide-related impurity at 0.10% or more be identified and that any new impurity be held to 0.5% or less, with an immunogenicity assessment.
- FDA evaluated 48 GLP-1 ingredient manufacturing sites and found 21% noncompliant, a finding it cites in its import alert for GLP-1 active ingredients.
- FDA says semaglutide sodium and semaglutide acetate are different active ingredients from the approved drug, with no known lawful basis for compounding.
The molecule both routes are trying to make
Semaglutide is a modified version of the human hormone GLP-1, with 94% sequence homology to it (Ozempic prescribing information). The U.S. label describes three key changes. Position 8 is modified to resist breakdown by the DPP-4 enzyme. The lysine at position 26 carries a hydrophilic spacer and a C18 fatty diacid, which binds albumin in the blood and stretches the drug's action to once weekly. A minor change at position 34 ensures only one fatty diacid attaches. The molecular formula is C187H291N45O59, with a molecular weight of 4,113.58 g/mol (same source).
That side chain matters for manufacturing. Neither yeast nor a standard peptide synthesizer produces it on its own. Whatever the route, the finished molecule needs a chemistry step to add it, and every step is a chance for by-products.
Novo's route: yeast first, chemistry second
The U.S. label says simply that "the peptide backbone is produced by yeast fermentation" (Ozempic label). The European Medicines Agency's public assessment report for Ozempic gives more detail. It describes a "fermentation process in yeast cells, recovery and purification of semaglutide precursor," after which "the semaglutide precursor is subjected to a synthetic modification process and purified" (EMA assessment report).
The EMA report states that the recovery, purification and modification steps are all run as batch processes with unique batch numbers. It also notes that product-related impurities form as by-products during fermentation, recovery and modification, and that the major impurity peaks were isolated and identified using high-resolution liquid chromatography and mass spectrometry (EMA). In other words, the reference product's impurities are known, characterized and controlled within an approved application.
The synthetic route: building the chain chemically
A synthetic manufacturer skips the yeast. The amino-acid chain is assembled chemically, typically by adding protected amino acids one after another, or by joining shorter pre-made fragments, then attaching the side chain, cleaving and purifying the product. Done well, the result is the same semaglutide molecule.
The trade-off is in the impurity profile. FDA's guidance on synthetic peptides explains that "peptide-related impurities include amino acid sequences related to, but different from, that of the active ingredient," which can arise "as a result of insertion, deletion, or other modifications (e.g., oxidation or glycosylation)." By contrast, "host cell-related impurities," such as host cell DNA and proteins, "occur only in rDNA-origin peptide drug products" (FDA draft guidance, October 2017).
| Feature | Recombinant (yeast) route | Synthetic route |
|---|---|---|
| Where the backbone comes from | Precursor expressed by genetically engineered Saccharomyces cerevisiae | Chemical assembly of amino acids or peptide fragments |
| Side chain attachment | Chemical modification after fermentation | Chemical, during or after assembly |
| Host cell impurities (yeast DNA, proteins) | Possible; must be controlled | Not applicable |
| Peptide-related impurities (insertions, deletions, oxidation) | Possible | Possible; profile depends on process |
| Documented example | Novo Nordisk's Ozempic, per the EMA report and U.S. label | The route FDA's synthetic-generic guidance addresses |
Source: EMA Ozempic assessment report, Ozempic label, FDA draft guidance on synthetic peptides.
Want a product with a known impurity profile?
FDA-approved GLP-1 medications are made under reviewed, inspected manufacturing processes.
Paid links. We may earn a commission; it never changes what we write. See all options. Compounded medications are not FDA-approved.
Why FDA cares about peptide impurities
The concern is not only purity for its own sake. FDA's guidance warns that "differences in impurities, particularly peptide-related impurities, may affect the safety or effectiveness" of a peptide product, and that in some circumstances these impurities "may create the potential for differences in immunogenicity" (FDA draft guidance). Immunogenicity means the body's immune system reacting to the drug, which can range from injection-site reactions to antibodies that blunt the drug's effect.
The generic framework
FDA finalized its guidance on ANDAs for highly purified synthetic peptides that reference drugs of recombinant origin in May 2021. It covers five named peptides: glucagon, liraglutide, nesiritide, teriparatide and teduglutide (FDA guidance page). Semaglutide is not on that list, but the framework shows how FDA thinks about a synthetic copy of a yeast-made peptide.
The 2017 draft set out specific expectations. Applicants should identify each peptide-related impurity at "0.10 percent of the drug substance or greater." Any new impurity not found in the reference product should be "no more than 0.5 percent," backed by data that it does not contain sequences with increased affinity for immune-system MHC molecules. Impurities shared with the reference product should be at the same or lower level (FDA draft guidance). If clinical data are needed to assess immunogenicity, the draft says an ANDA is not the right pathway.
| Expectation in FDA's 2017 draft | Threshold |
|---|---|
| Identify each peptide-related impurity | At or above 0.10% of the drug substance |
| New specified impurity not in the reference drug | No more than 0.5%, with immunogenicity data |
| Impurity also found in the reference drug | Same as or lower than the reference level |
Source: FDA draft guidance, October 2017. The guidance was finalized in May 2021.
Liraglutide shows the path works
Liraglutide, semaglutide's daily predecessor, is a practical example. Novo makes Victoza and Saxenda, and FDA's drug shortage listing for liraglutide now shows generic products from Hikma and Meitheal alongside a Teva-distributed product (FDA Drug Shortages). Liraglutide is one of the five peptides named in FDA's synthetic-generic guidance. Semaglutide is further behind. FDA announced its first tentative approval of a generic semaglutide injection, an application from Apotex, on April 10, 2026, but a tentative approval does not permit marketing while patent or exclusivity barriers remain, and the timeline for market entry is uncertain (HCPLive).
The compounding ingredient problem
Generic approval runs through FDA review of the manufacturing process and impurity data. Compounding does not. That is the gap FDA has flagged repeatedly.
Salt forms are not the same ingredient
Some compounders have used semaglutide sodium or semaglutide acetate. FDA says these "are different active ingredients than are used in the approved drugs," that it does not know whether they share the same chemical and pharmacologic properties, and that it is "not aware of any lawful basis for their use in compounding" (FDA).
An import alert for GLP-1 ingredients
FDA's Import Alert 66-80 allows detention without physical examination of GLP-1 bulk drug substances, with a "green list" of firms exempted. FDA's stated reasoning is direct: 503A pharmacies are exempt from manufacturing quality (CGMP) requirements, so ingredient problems may not be caught during compounding. Of 48 GLP-1 ingredient sites FDA evaluated, "it found that 21% were noncompliant," and some firms registered, offered ingredients for import, refused records requests and then deregistered (FDA Import Alert 66-80). The alert covers semaglutide, tirzepatide, liraglutide and other GLP-1 ingredients, and the current version is dated October 9, 2026 (same source).
FDA's consumer page describes the purpose as helping to stop GLP-1 ingredients "that have potential quality concerns" from entering the U.S. supply chain, while not blocking legal imports from compliant manufacturers (FDA).
What this means for patients
"Synthetic" is not a red flag by itself. FDA's own framework contemplates synthetic generics of yeast-made peptides, and liraglutide shows they can reach the market. The meaningful question is whether anyone with authority has characterized and limited the impurities in the specific ingredient you are receiving.
For an approved brand or generic, FDA has reviewed that data. For a compounded product, the answer depends on the ingredient supplier, whether it is the base molecule or a salt, and what testing the pharmacy can show. Stability after compounding is a separate question that we cover in our chemistry article. If you use or are considering a compounded product, reasonable questions for your pharmacist include who made the active ingredient, whether it is semaglutide base, and whether a certificate of analysis lists identified impurities. Talk with your prescriber about whether an approved product fits your needs.
Compare approved options
See current pricing for FDA-approved semaglutide and other GLP-1 treatments.
Paid links. We may earn a commission; it never changes what we write. See all options. Compounded medications are not FDA-approved.
Frequently asked questions
How does Novo Nordisk make semaglutide?
According to the EMA assessment report, Novo produces a semaglutide precursor by fermentation in genetically engineered Saccharomyces cerevisiae yeast, purifies it, then chemically modifies it to add the fatty-acid side chain and purifies the result.
Is synthetic semaglutide the same as the yeast-made version?
Chemical synthesis can produce the same molecule, but the impurity profile differs. Synthetic routes avoid yeast host-cell impurities but can create peptide-related impurities such as sequences with inserted or deleted amino acids.
What impurity limits has FDA proposed for synthetic generic peptides?
FDA's 2017 draft guidance proposed identifying each peptide-related impurity at 0.10% or more and holding any new impurity to 0.5% or less, with data on immunogenicity risk. The guidance was finalized in May 2021 for five named peptides.
Why is FDA concerned about compounded semaglutide ingredients?
FDA found 21% of 48 GLP-1 ingredient sites it evaluated were noncompliant and created Import Alert 66-80. It also says semaglutide sodium and acetate salts are different active ingredients with no known lawful basis for compounding.
Sources
- European Medicines Agency: Ozempic public assessment report
- Ozempic (semaglutide) injection prescribing information
- FDA guidance: ANDAs for Certain Highly Purified Synthetic Peptide Drug Products That Refer to Listed Drugs of rDNA Origin (May 2021)
- FDA draft guidance: ANDAs for Certain Highly Purified Synthetic Peptide Drug Products (October 2017)
- FDA: FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss
- FDA Import Alert 66-80: GLP-1 receptor agonist bulk drug substances
- FDA Drug Shortages: Liraglutide Injection
- HCPLive: FDA gives tentative approval of ANDA for generic semaglutide injection (April 2026)
Medical disclaimer: This article is general information, not medical advice, and does not replace a licensed clinician who knows your history. Approvals, labels, coverage and prices change; check the linked sources and talk with your prescriber or pharmacist before making decisions about any medication.